Long regulatory RNAs

Humans and worms show striking phenotypic differences despite the fact that both genomes encode a comparable number of protein coding genes (~20,000). These observations suggest that biological complexity cannot be accounted for by protein coding genes alone. Emerging data from different areas of investigation suggest that the information which programs biological complexity is entwined in noncoding regulatory RNA. Powerful novel sequencing technologies have enabled the discovery of an entire new world of long and short noncoding RNAs. Regulatory noncoding RNAs play an established role in epigenetic mechanisms such as parental imprinting or X chromosome inactivation, cutting-edge results, however, indicate a much broader impact. Recent evidence suggests that noncoding regulatory RNAs are involved in disease, development and aging. The expression of several tumour suppressor genes is controlled by both small and long regulatory RNAs and specific noncoding RNAs are indicative for tumour development and disease progression. In addition, antisense RNAs play a role in an inherited form of anaemia and in Alzheimer’s disease. It comes as no surprise that regulatory RNAs raise the justified promise of seminal therapeutic applications.

+ show speakers and program
Reuven Agami, The Netherlands Cancer Institute, Amsterdam, NL
Laurie A. Boyer, Massachusetts Medical School, Boston, USA
Sven Diederichs, German Cancer Research Center, Heidelberg, DE
Stefanie Dimmeler, University of Frankfurt, Frankfurt, DE
Peter Fraser, Peter Fraser, Babraham Institute, Cambridge, UK
Mitchell Guttmann, California Institute of Technology, Pasadena, USA
Maite Huarte, University of Navarra, Pamplona, ES
Nicola Illing, University of Cape Town, Cape Town, RSA
Noora Kotaja, University of Turku, Turku, Fi
Anders H Lund, University of Copenhagen, Copenhagen, DK
Gunter Meister, University of Regenburg, Regensburg, DE
Donal O'Carroll, EMBL, Monterotondo, IT
Pier-Paolo Pandolfi, Harvard Medical School, Boston, USA
Florian Pauler, Center for Molecular Medicine, Vienna, AT
Laura Poliseno, Istituto Toscano Tumori, Pisa, IT
Nikolaus Rajewski, Max Delbruck Center for Molecular Medicine, DE
Alena Shkumatava, Institut Curie, Paris, Fr
Petr Svoboda, Institute of Molecular Genetics, Prague, CZ
Andreas Werner, Newcastle University, Newcastle, UK
Anton Wutz, ETH, Zurich, Switzerland
ProgrammeHow to participate
ApplicationRegistrationGrants & Fees
Chairs & SpeakersPartners & Sponsors
PartnersSponsorship Opportunities
Practical Information
Conference VenueAccommodation & MealsParticipant GuidelinesTransportationOther Services

13 Sep - 18 Sep 2014

meeting website